Skip to main content
Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
14.54
+0.18 (1.25%)
At close: Mar 28, 2025, 4:00 PM
14.53
-0.01 (-0.05%)
After-hours: Mar 28, 2025, 7:56 PM EDT

Cartesian Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
38.9126110.7885.08
Revenue Growth (YoY)
49.64%-76.53%30.21%-
Cost of Revenue
44.9165.6672.3868.74
Gross Profit
-5.99-39.6638.416.34
Selling, General & Admin
29.5334.7523.8620.94
Operating Expenses
29.5334.7523.8620.94
Operating Income
-35.52-74.4114.54-4.6
Interest Expense
--2.83-3.03-2.84
Interest & Investment Income
7.394.962.070.04
Currency Exchange Gain (Loss)
-0.04-0.02-
Other Non Operating Income (Expenses)
-3.73-136.1621.21-2.32
EBT Excluding Unusual Items
-31.86-208.434.77-9.72
Merger & Restructuring Charges
-0.8-11.3--
Asset Writedown
-7.58-0.71--
Other Unusual Items
-36.9-18.3--
Pretax Income
-77.14-238.7134.77-9.72
Income Tax Expense
0.29-19-0.6115.97
Net Income
-77.42-219.7135.38-25.69
Preferred Dividends & Other Adjustments
-37.55--
Net Income to Common
-77.42-257.2635.38-25.69
Shares Outstanding (Basic)
17554
Shares Outstanding (Diluted)
17554
Shares Change (YoY)
235.72%6.33%27.59%-
EPS (Basic)
-4.48-49.767.33-6.74
EPS (Diluted)
-4.49-49.762.98-6.74
Free Cash Flow
-32.77-51.37-32.83-61.47
Free Cash Flow Per Share
-1.89-9.94-6.75-16.13
Gross Margin
-15.40%-152.50%34.66%19.21%
Operating Margin
-91.27%-286.13%13.12%-5.40%
Profit Margin
-198.97%-989.31%31.94%-30.19%
Free Cash Flow Margin
-84.21%-197.53%-29.64%-72.25%
EBITDA
-34.37-73.5615.83-3.35
EBITDA Margin
-88.32%-282.89%14.29%-3.93%
D&A For EBITDA
1.150.841.291.25
EBIT
-35.52-74.4114.54-4.6
EBIT Margin
-91.27%-286.13%13.12%-5.40%
Revenue as Reported
38.9126--
Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q